SmartTRAK attended key sessions on ADM use and reports on the latest trends impacting the US Breast Matrices Market.

The American Society of Plastic Surgeons (ASPS) and various manufacturers continue to pursue IDEs to gain an indication to use an acellular dermal matrix (ADM) in breast reconstruction. At Plastic Surgery: The Meeting 2023 (PSTM2023), held in Austin, TX, SmartTRAK attended key sessions on ADM use and reports on the latest trends affecting the market for ADMs.

In this article, SmartTRAK discusses the evolution and growth of ADMs and shares observations from the meeting across primarily two sessions covering breast reconstruction: They are:

• “Support Group: A Mesh For Each Patient and Getting Away Without It”
• “Back to the Future: Moving Forward or Going Back with Pre and Subpectoral Reconstruction.”

Just click the button below to download and read the complete detailed "Plastic Surgery: The Meeting 2023" article by Doug Devens, SmartTRAK's IT Product Director and Sr Analyst, Wound.

Breast Matrices rebound and grow modestly as AbbVie’s competitors take over market share. Biosynthetic and hybrid xenograft hernia matrices continue to drive growth in Hernia Matrices.

The US Surgical Matrices Market resumed its pre-pandemic trends, gaining +3.2% YoY according to SmartTRAK Financial Dashboard. AbbVie* and Becton Dickinson* (BD) remained in first and second positions, respectively, in the Q422 Surgical Matrices market. AbbVie held on to its leadership despite  a -4.4% YoY decline, while BD gained +6.1% YoY.

Among the many topics covered in detail in our comprehensive Q422 US Surgical Matrices Market Recap* are: